stanford v stanford v stanford v (usually spoken as stanford five), is a chemotherapy regimen (with accompanying radiation therapy) intended as a first-line treatment for hodgkin lymphoma. the regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as abvd. the chemical agents used are: a mustard derivative such as cyclophosphamide, chlormethine or ifosfamide doxorubicin, an anti-tumor antibiotic vinblastine, an alkaloid cell toxin vincristine, another alkaloid cell toxin bleomycin, another anti-tumor antibiotic etoposide, a dna toxin prednisone, a corticosteroid drug regimen drugdosemodedays doxorubicin25 mg/m2ivdays 1 and 15 vinblastine6 mg/m2ivdays 1 and 15 chlormethine6 mg/m2ivday 1 vincristine1.4 mg/m2 (max 2 mg)ivdays 8 and 22 bleomycin5 units/m2ivdays 8 and 22 etoposide60 mg/m2ivdays 15, 16 prednisone40 mg/m2poq2d the chemotherapy part of stanford v treatment can last anywhere from 8 to 12 weeks, depending on the staging of the disease. in many cases, this is followed by radiation therapy for anywhere from 2 to 6 weeks to the affected areas of the body. stanford v is a more rigorously administered form of chemotherapy, with treatments roughly twice as fast as those of other hodgkin lymphoma treatments. however, in a randomized controlled study, stanford v was inferior to abvd. this study has been criticized for not adhering to the proper stanford v protocol. specifically, the radiation therapy component following chemotherapy was not properly administered in the italian study. a retrospective study from the memorial sloan-kettering cancer center displayed results similar to the stanford cancer center's own experience. the study concluded that, "stanford v with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced hl."